New Findings from University of Alexandria Describe Advances in Tuberculosis (Respirable nanocarriers as a promising strategy for antitubercular drug delivery)
By a News Reporter-Staff News Editor at Tuberculosis Week -- Investigators publish new report on Mycobacterium Infections. According to news reporting originating from Alexandria, Egypt, by NewsRx correspondents, research stated, "Tuberculosis is considered a fatal respiratory infectious disease that represents a global threat, which must be faced. Despite the availability of oral conventional anti-tuberculosis therapy, the disease is characterized by high progression."
Our news editors obtained a quote from the research from the University of Alexandria, "The leading causes are poor patient compliance and failure to adhere to the drug regimen primarily due to systemic toxicity. In this context, inhalation therapy as a non-invasive route of administration is capable of increasing local drug concentrations in lung tissues, the primary infection side, by passive targeting as well as reducing the risk of systemic toxicity and hence improving the patient compliance. Nanotechnology represents a promising strategy in the development of inhaled drug delivery systems. Nanocarriers can improve the drug effectiveness and decrease the expected side effects as consequences of their ability to target the drug to the infected area as well as sustain its release in a prolonged manner. The current review summarizes the state-of-the-art in the development of inhaled nanotechnological carriers confined currently available anti-tuberculosis drugs (anti TB) for local and targeting drug delivery specifically, polymeric nanoparticles, solid lipid nanoparticles, nanoliposomes and nanomicelles. Moreover, complexes and ion pairs are also reported."
According to the news editors, the research concluded: "The impact and progress of nanotechnology on the therapeutic effectiveness and patient adherence to anti TB regimen are addressed."
For more information on this research see: Respirable nanocarriers as a promising strategy for antitubercular drug delivery. Journal of Controlled Release, 2014;187():183-197. Journal of Controlled Release can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Journal of Controlled Release - www.elsevier.com/wps/product/cws_home/502690)
The news editors report that additional information may be obtained by contacting M.M. Mehanna, University of Alexandria, Fac Pharm, Ind Pharm Department, Alexandria 21521, Egypt. Additional authors for this research include S.M. Mohyeldin and N.A. Elgindy (see also Mycobacterium Infections).
Keywords for this news article include: Egypt, Africa, Therapy, Alexandria, Nanocarriers, Nanoparticle, Nanotechnology, Drug Delivery Systems, Emerging Technologies, Gram-Positive Bacteria, Mycobacterium Infections, Actinomycetales Infections, Mycobacterium Tuberculosis
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC